209 related articles for article (PubMed ID: 32727801)
1. Prognostic Impact of Desmoplastic Reaction Evaluation for Intrahepatic Cholangiocarcinoma.
Kojima S; Hisaka T; Midorikawa R; Naito Y; Akiba J; Tanigawa M; Yano H; Akagi Y; Okuda K
Anticancer Res; 2020 Aug; 40(8):4749-4754. PubMed ID: 32727801
[TBL] [Abstract][Full Text] [Related]
2. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
3. Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1α for Intrahepatic Cholangiocarcinoma.
Ohta S; Morine Y; Imura S; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Yamada S; Wada Y; Yamashita S; Bando Y; Shimada M
Anticancer Res; 2019 Nov; 39(11):6025-6033. PubMed ID: 31704828
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma].
Tang X; Zhang J; Chen Y; Lan Z; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):662-6. PubMed ID: 25564055
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases.
Laohaviroj M; Chamgramol Y; Pairojkul C; Mulvenna J; Sripa B
Asian Pac J Cancer Prev; 2016; 17(1):201-5. PubMed ID: 26838210
[TBL] [Abstract][Full Text] [Related]
6. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.
Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L
J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
8. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
9. Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis.
Chen Y; Hong Z; Lu S; Zhang N; Rong G; Chang X; Liu Z; Bai W; Dong Z; Gao X; Zeng Z; Lu Y
Med Sci Monit; 2018 Nov; 24():7875-7882. PubMed ID: 30390420
[TBL] [Abstract][Full Text] [Related]
10. Intrahepatic cholangiocarcinoma: a clinicopathologic study of 37 resected cases.
Zhu HF; Li J; Huang L; Yan YQ
Hepatogastroenterology; 2013; 60(122):263-7. PubMed ID: 23574653
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression.
Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M
Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859
[TBL] [Abstract][Full Text] [Related]
12. Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma.
Aishima S; Taguchi K; Terashi T; Matsuura S; Shimada M; Tsuneyoshi M
Mod Pathol; 2003 Oct; 16(10):1019-27. PubMed ID: 14559985
[TBL] [Abstract][Full Text] [Related]
13. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
14. Urinary Metabolites Diagnostic and Prognostic of Intrahepatic Cholangiocarcinoma.
Haznadar M; Diehl CM; Parker AL; Krausz KW; Bowman ED; Rabibhadana S; Forgues M; Bhudhisawasdi V; Gonzalez FJ; Mahidol C; Budhu A; Wang XW; Ruchirawat M; Harris CC
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1704-1711. PubMed ID: 31358519
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of interleukin-35 in intrahepatic cholangiocarcinoma is a prognostic indicator after curative resection.
Zhang MX; Gan W; Jing CY; Zheng SS; Zhang J; Shen HJ; Xu X; Lin JJ; Zhang BH; Qiu SJ
Cancer Sci; 2018 Apr; 109(4):1195-1206. PubMed ID: 29446854
[TBL] [Abstract][Full Text] [Related]
16. Synchronous double cancers of primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a case report and review of the literature.
Wu C; Bai DS; Jiang GQ; Jin SJ
World J Surg Oncol; 2014 Nov; 12():337. PubMed ID: 25385169
[TBL] [Abstract][Full Text] [Related]
17. A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score.
Jiang W; Zeng ZC; Tang ZY; Fan J; Sun HC; Zhou J; Zeng MS; Zhang BH; Ji Y; Chen YX
Ann Oncol; 2011 Jul; 22(7):1644-1652. PubMed ID: 21212156
[TBL] [Abstract][Full Text] [Related]
18. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
Hunt JP; Varnholt H
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
[No Abstract] [Full Text] [Related]
19. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.
Shen WF; Zhong W; Xu F; Kan T; Geng L; Xie F; Sui CJ; Yang JM
World J Gastroenterol; 2009 Dec; 15(47):5976-82. PubMed ID: 20014463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
